Health Canada finalises guidance on biosimilars
This article was originally published in Scrip
Executive Summary
Health Canada has issued its much-awaited final guidance on the authorisation of subsequent entry biologics (SEBs), also referred to as biosimilars or follow-on biologics in some jurisdictions.